Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Kamada Ltd. (KMDA : NSDQ)

• Company Description    Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel. Number of Employees: 462

• Price / Volume Information    Yesterday's Closing Price: $7.83 Daily Weekly Monthly 20 Day Moving Average: 51,829 shares Shares Outstanding: 57.51 (millions) Market Capitalization: $450.26 (millions) Beta: 0.86 52 Week High: $9.35 52 Week Low: $6.50 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -5.32% -9.95% 12 Week -12.12% -18.76% Year To Date 10.91% 1.84%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2 HOLTZMAN ST. SCIENCE PARK - REHOVOT,L3 7670402 ISR ph: 972-8940-6472 fax: 972-8940-6473 ir@kamada.com http://www.kamada.com

• General Corporate Information    Officers Amir London - Chief Executive Officer Lilach Asher-Topilsky - Chair of the Board of Directors Eran Nir - Chief Operating Officer Chaime Orlev - Chief Financial Officer Uri Botzer - Director Peer Information Kamada Ltd. (CORR.) Kamada Ltd. (RSPI) Kamada Ltd. (CGXP) Kamada Ltd. (BGEN) Kamada Ltd. (GTBP) Kamada Ltd. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: M6240T109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/12/26 Share - Related Items Shares Outstanding: 57.51 Most Recent Split Date: (:1) Beta: 0.86 Market Capitalization: $450.26 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 2.39% Current Fiscal Quarter EPS Consensus Estimate: $0.12 Indicated Annual Dividend: $0.19 Current Fiscal Year EPS Consensus Estimate: $0.44 Payout Ratio: 0.54 Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: 0.50 Estmated Long-Term EPS Growth Rate: 25.00% Last Dividend Paid: 03/23/2026 - $0.19 Next EPS Report Date: 08/12/26

• Fundamental Ratios P/E Current FY Estimate: 17.93 Trailing 12 Months: 22.37 PEG Ratio: 0.72 Price Ratios Price/Book: 1.74 Price/Cash Flow: 12.82 Price / Sales: 2.48 EPS Growth vs. Year Ago Period: 0.00% vs. Previous Quarter: 16.67% Sales Growth vs. Year Ago Period: 2.78% vs. Previous Quarter: 1.26% ROE 03/31/26 - 7.73 12/31/25 - 7.72 09/30/25 - 7.89 ROA 03/31/26 - 5.41 12/31/25 - 5.39 09/30/25 - 5.48 Current Ratio 03/31/26 - 3.33 12/31/25 - 4.07 09/30/25 - 4.03 Quick Ratio 03/31/26 - 1.90 12/31/25 - 2.28 09/30/25 - 2.24 Operating Margin 03/31/26 - 11.21 12/31/25 - 11.19 09/30/25 - 11.70 Net Margin 03/31/26 - 11.21 12/31/25 - 11.19 09/30/25 - 11.70 Pre-Tax Margin 03/31/26 - 12.24 12/31/25 - 13.00 09/30/25 - 12.12 Book Value 03/31/26 - 4.51 12/31/25 - 4.68 09/30/25 - 4.61 Inventory Turnover 03/31/26 - 1.27 12/31/25 - 1.26 09/30/25 - 1.21 Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©